SGRYSurgery Partners, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for a decline (~−2% a year). The price demands less than its three-year revenue growth of 8% a year, expectations look modest.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SGRY's price assumes
Today's price asks for −2.3% free cash flow growth a year; over the last three years Surgery Partners, Inc. delivered +37%, so the price asks for less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 9.1%
Free cash flow yield · Medical Care Facilities median 6.0%
- Growth the price implies
- −2.3%
Growth the price implies · The price pays for −2.3% free cash flow growth a year for a decade; the business has delivered +37% a year over the last three.
- Price / book
- 1.23
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.23
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 14.6
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.66
- Free cash flow, trailing twelve months
- $188M
- Market capitalisation130.9 million shares, counted Aug 3, 2026
- $2.06B
- 3-year revenue growth
- +8.2%
- 3-year free cash flow growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.